Citigroup maintains a Buy on Jubilant Life Sciences as deals with innovator companies will not only help its growth and profitability, but also point to a growing traction in its contract manufacturing organisation business. However, high company debt remains a concern.

Jindal Saw Ltd

Recommendation:Buy

CMP:Rs 152

Target:Rs 210

Broker's consensus:Buy (11) - Hold (1) - Sell (4)

HSBC initiates coverage on Jindal Saw with an Overweight rating. While the operating environment is difficult, the company is well-positioned in terms of global expansion and commissioning of mines. In the domestic market, rising input costs are a cause for concern.

Nomura maintains a Buy rating on Lupin. And that's because foreign pharmaceutical companies have announced that they have settled the patent litigation on diabetes drug Glumetza with Lupin regarding FTF opportunity, with high entry barriers for larger players.

Titan Industries Ltd

Recommendation:Sell

CMP:Rs 225

Target:Rs 221

Broker's consensus:Buy (18) - Hold (7) - Sell (4)

Goldman Sachs downgrades Titan Industries to Neutral, as it believes that the recent outperformance in the stock suitably prices in the company's growth potential. It also sees limited likelihood of earnings upgrades for Titan due to uncertain demand scenario for gold jewellery.

Disclaimer: Investor's Guide does not accept responsibility for consequences of financial decisions taken by readers on the basis of information provided herein. The aim is to provide a reasonably accurate picture of financial and related opportunities based on information available with us. The Times of India Group has invested in several companies; a list of the names of some of the investee companies can be viewed at http://www.brandcapital.co.in